Peptomyc, a spin-off of the Vall d'Hebron Institute of Oncology (VHIO) and the Catalan Institute of Research and Advanced Studies (ICREA) and CataloniaBio & HealthTech member, has kicked off its Phase I/IIa clinical trial on the first Myc inhibitor. Myc is a gene involved in the development of most human cancers.

On 4 May, the first patient was treated with this therapy at Vall d'Hebron University Hospital in Barcelona under the supervision of Dr Elena Garralda, director of the Research Unit for Molecular Therapy of Cancer (UITM) and principal investigator of VHIO’s Early Clinical Drug Development Group.

The objective of this study is to evaluate the safety of OMO-103, as well as its preliminary anti-tumor efficacy.

In Phase I, the other participating centres are HM Sanchinarro University Hospital and Jiménez Díaz Foundation University Hospital in Madrid. In Phase II, recruitment will be opened to more centres in Europe.

More information

Photo: from left to right, Marie-Eve Beaulieu, co-founder and CSO of Peptomyc, Laura Soucek, co-founder and CEO, and Manuela Niewel, CMO.

You may also be interested in:

• Peptomyc closes €11.4 million equity funding led by Aurora Science
• Peptomyc appoints Manuela Niewel as Chief Medical Officer
• Peptomyc gets €2.2 million through SME Instrument

Want to know more about Peptomyc? We recommend this video of CataloniaBio & HealthTech interviewing them: